269 related articles for article (PubMed ID: 30501012)
1. Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva.
Wentworth KL; Masharani U; Hsiao EC
Br J Clin Pharmacol; 2019 Jun; 85(6):1180-1187. PubMed ID: 30501012
[TBL] [Abstract][Full Text] [Related]
2. Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.
Chakkalakal SA; Uchibe K; Convente MR; Zhang D; Economides AN; Kaplan FS; Pacifici M; Iwamoto M; Shore EM
J Bone Miner Res; 2016 Sep; 31(9):1666-75. PubMed ID: 26896819
[TBL] [Abstract][Full Text] [Related]
3. Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity.
Lees-Shepard JB; Nicholas SE; Stoessel SJ; Devarakonda PM; Schneider MJ; Yamamoto M; Goldhamer DJ
Elife; 2018 Sep; 7():. PubMed ID: 30226468
[TBL] [Abstract][Full Text] [Related]
4. Acute and chronic rapamycin use in patients with Fibrodysplasia Ossificans Progressiva: A report of two cases.
Kaplan FS; Zeitlin L; Dunn SP; Benor S; Hagin D; Al Mukaddam M; Pignolo RJ
Bone; 2018 Apr; 109():281-284. PubMed ID: 29241828
[TBL] [Abstract][Full Text] [Related]
5. Surgical management of bilateral hip fractures in a patient with fibrodysplasia ossificans progressiva treated with the RAR-γ agonist palovarotene: a case report.
Singh S; Kidane J; Wentworth KL; Motamedi D; Morshed S; Schober AE; Hsiao EC
BMC Musculoskelet Disord; 2020 Apr; 21(1):204. PubMed ID: 32245464
[TBL] [Abstract][Full Text] [Related]
6. Special considerations for clinical trials in fibrodysplasia ossificans progressiva (FOP).
Hsiao EC; Di Rocco M; Cali A; Zasloff M; Al Mukaddam M; Pignolo RJ; Grunwald Z; Netelenbos C; Keen R; Baujat G; Brown MA; Cho TJ; De Cunto C; Delai P; Haga N; Morhart R; Scott C; Zhang K; Diecidue RJ; Friedman CS; Kaplan FS; Eekhoff EMW
Br J Clin Pharmacol; 2019 Jun; 85(6):1199-1207. PubMed ID: 30281842
[TBL] [Abstract][Full Text] [Related]
7. Recent progress in drug development for fibrodysplasia ossificans progressiva.
Meng X; Wang H; Hao J
Mol Cell Biochem; 2022 Oct; 477(10):2327-2334. PubMed ID: 35536530
[TBL] [Abstract][Full Text] [Related]
8. A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton.
Kaplan FS; Glaser DL; Pignolo RJ; Shore EM
Expert Opin Biol Ther; 2007 May; 7(5):705-12. PubMed ID: 17477807
[TBL] [Abstract][Full Text] [Related]
9. Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP): Results of a Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial.
Pignolo RJ; Baujat G; Hsiao EC; Keen R; Wilson A; Packman J; Strahs AL; Grogan DR; Kaplan FS
J Bone Miner Res; 2022 Oct; 37(10):1891-1902. PubMed ID: 35854638
[TBL] [Abstract][Full Text] [Related]
10. Role of altered signal transduction in heterotopic ossification and fibrodysplasia ossificans progressiva.
Shore EM; Kaplan FS
Curr Osteoporos Rep; 2011 Jun; 9(2):83-8. PubMed ID: 21340697
[TBL] [Abstract][Full Text] [Related]
11. Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1
Convente MR; Chakkalakal SA; Yang E; Caron RJ; Zhang D; Kambayashi T; Kaplan FS; Shore EM
J Bone Miner Res; 2018 Feb; 33(2):269-282. PubMed ID: 28986986
[TBL] [Abstract][Full Text] [Related]
12. High-throughput screening for modulators of ACVR1 transcription: discovery of potential therapeutics for fibrodysplasia ossificans progressiva.
Cappato S; Tonachini L; Giacopelli F; Tirone M; Galietta LJ; Sormani M; Giovenzana A; Spinelli AE; Canciani B; Brunelli S; Ravazzolo R; Bocciardi R
Dis Model Mech; 2016 Jun; 9(6):685-96. PubMed ID: 27125279
[TBL] [Abstract][Full Text] [Related]
13. Palovarotene: First Approval.
Hoy SM
Drugs; 2022 Apr; 82(6):711-716. PubMed ID: 35384641
[TBL] [Abstract][Full Text] [Related]
14. Reduction of New Heterotopic Ossification (HO) in the Open-Label, Phase 3 MOVE Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP).
Pignolo RJ; Hsiao EC; Al Mukaddam M; Baujat G; Berglund SK; Brown MA; Cheung AM; De Cunto C; Delai P; Haga N; Kannu P; Keen R; Le Quan Sang KH; Mancilla EE; Marino R; Strahs A; Kaplan FS
J Bone Miner Res; 2023 Mar; 38(3):381-394. PubMed ID: 36583535
[TBL] [Abstract][Full Text] [Related]
15. [Genetic basis for skeletal disease. Establishment of novel treatments for fibrodysplasia ossificans progressiva (FOP)].
Katagiri T
Clin Calcium; 2010 Aug; 20(8):1204-11. PubMed ID: 20675931
[TBL] [Abstract][Full Text] [Related]
16. Mast cell inhibition as a therapeutic approach in fibrodysplasia ossificans progressiva (FOP).
Brennan TA; Lindborg CM; Bergbauer CR; Wang H; Kaplan FS; Pignolo RJ
Bone; 2018 Apr; 109():259-266. PubMed ID: 28851540
[TBL] [Abstract][Full Text] [Related]
17. Hints on transcriptional control of essential players in heterotopic ossification of Fibrodysplasia Ossificans Progressiva.
Ravazzolo R; Cappato S; Bocciardi R
Bone; 2018 Apr; 109():187-191. PubMed ID: 29100956
[TBL] [Abstract][Full Text] [Related]
18. Early clinical observations on the use of imatinib mesylate in FOP: A report of seven cases.
Kaplan FS; Andolina JR; Adamson PC; Teachey DT; Finklestein JZ; Ebb DH; Whitehead B; Jacobs B; Siegel DM; Keen R; Hsiao E; Pignolo RJ
Bone; 2018 Apr; 109():276-280. PubMed ID: 28736245
[TBL] [Abstract][Full Text] [Related]
19. Neofunction of ACVR1 in fibrodysplasia ossificans progressiva.
Hino K; Ikeya M; Horigome K; Matsumoto Y; Ebise H; Nishio M; Sekiguchi K; Shibata M; Nagata S; Matsuda S; Toguchida J
Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15438-43. PubMed ID: 26621707
[TBL] [Abstract][Full Text] [Related]
20. Clinically applicable antianginal agents suppress osteoblastic transformation of myogenic cells and heterotopic ossifications in mice.
Yamamoto R; Matsushita M; Kitoh H; Masuda A; Ito M; Katagiri T; Kawai T; Ishiguro N; Ohno K
J Bone Miner Metab; 2013 Jan; 31(1):26-33. PubMed ID: 23011467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]